Anavex

$5.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.47 (+8.94%) Today
+$0.02 (+0.26%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Anavex and other stocks, options, and ETFs commission-free!

About AVXL

Anavex Life Sciences Corp. Common Stock, also called Anavex, is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Read More Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY. The listed name for AVXL is Anavex Life Sciences Corp. Common Stock.

Employees
16
Headquarters
New York, New York
Founded
2004
Market Cap
344.59M
Price-Earnings Ratio
Dividend Yield
Average Volume
2.28M
High Today
$5.74
Low Today
$5.30
Open Price
$5.37
Volume
2.10M
52 Week High
$6.31
52 Week Low
$2.20

Collections

AVXL Earnings

-$0.17
-$0.11
-$0.06
$0.00
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Estimated
per share
Actual
Expected Dec 14, Pre-Market

You May Also Like